Natco Pharma Limited has launched Chlorantraniliprole (CTPR) 18.5% SC under the Brand Name of NATGEN in Indian Market. The company estimates the current market size of CTPR containing products in India to be over INR 20,000 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,020 INR | -0.48% | +2.52% | +25.74% |
05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.74% | 2.2B | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- NATCOPHARM Stock
- News NATCO Pharma Limited
- Natco Pharma Limited Launches Chlorantraniliprole